section name header

Indications

REMS


Betapace AF and Sotylize

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ARRHYTHMIAS, BRADYCARDIA, HF, PULMONARY EDEMA, orthostatic hypotension, peripheral vasoconstriction

Derm: itching, rash

EENT: blurred vision, dry eyes, nasal stuffiness

Endo: hyperglycemia, hypoglycemia

GI: constipation, diarrhea, nausea

GU: erectile dysfunction, libido

MS: arthralgia, back pain, muscle cramps

Neuro: fatigue, weakness, anxiety, dizziness, drowsiness, insomnia, memory loss, mental depression, mental status changes, nervousness, nightmares, paresthesia

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Ventricular Arrhythmias

Renal Impairment

Atrial Fibrillation/Atrial Flutter

Renal Impairment

US Brand Names

Betapace, Betapace AF, Sorine, Sotylize

Action

  • Blocks stimulation of beta1 (myocardial) and beta2 (pulmonary, vascular, and uterine) adrenergic receptor sites.
Therapeutic effects:
  • Suppression of arrhythmias.

Classifications

Therapeutic Classification: antiarrhythmics (class III)

Pharmacokinetics

Absorption: Well absorbed following oral administration (bioavailability 90–100%).

Distribution: Crosses the placenta; enters breast milk.

Metabolism/Excretion: Elimination is mostly renal.

Half-Life: 12 hr ( in renal impairment).

Canadian Brand Names

Rylosol

Time/Action Profile

(antiarrhythmic effects)

ROUTEONSETPEAKDURATION
POhr2–3 days8–12 hr

Patient/Family Teaching

Pronunciation

SOE-ta-lole

Code

NDC Code